Idiopathic membranous nephropathy: Management strategies

Drugs

Volumn 69, Issue 10, 2009, Pages 1303-1317

  Quaglia, Marco ^a   Stratta, Piero ^a  

^a UNIVERSITY OF EASTERN PIEDMONT   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE ANTAGONIST; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTICOAGULANT AGENT; AZATHIOPRINE; CHLORAMBUCIL; CORTICOSTEROID; CORTICOTROPIN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPYRIDAMOLE; DIURETIC AGENT; HYDROCHLOROTHIAZIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN; LOOP DIURETIC AGENT; METHYLPREDNISOLONE; METOLAZONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RITUXIMAB; TACROLIMUS; WARFARIN;

AGE DISTRIBUTION; AZOOSPERMIA; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; DIET RESTRICTION; DIET THERAPY; DISEASE COURSE; DRUG BLOOD LEVEL; DRUG DOSE SEQUENCE; DRUG INDICATION; DRUG WITHDRAWAL; EVENING DOSAGE; GLOMERULONEPHRITIS; HIGH RISK PATIENT; HUMAN; HYPERCHOLESTEROLEMIA; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FAILURE; KIDNEY FUNCTION; LEUKOPENIA; LOW DRUG DOSE; LUPUS ERYTHEMATOSUS NEPHRITIS; MEMBRANOUS GLOMERULONEPHRITIS; MONOTHERAPY; NEOPLASM; NEPHROTIC SYNDROME; NEPHROTOXICITY; PALLIATIVE THERAPY; PNEUMONIA; PRACTICE GUIDELINE; PROGNOSIS; PROTEINURIA; REMISSION; RENAL PROTECTION; REPEATED DRUG DOSE; REVIEW; SINGLE DRUG DOSE; THROMBOSIS; UNSPECIFIED SIDE EFFECT; VIRUS INFECTION;

AGED; ANTI-INFLAMMATORY AGENTS; GLOMERULONEPHRITIS, MEMBRANOUS; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY FAILURE, CHRONIC; NEPHROTIC SYNDROME;

EID: 67650410093     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/00003495-200969100-00002     Document Type: Review

References (103)

1. Lupo A, Bernich P, Antonucci F, et al. Kidney diseases with chronic renal failure in the Italian renal biopsy registries. G Ital Nefrol 2008; 25 Suppl. 44: 20-6
2. Haas M, Meehan SM, Karrsion TG, et al. Changing etiologies of unexplained adult nephrotic syndrome: a comparison between renal biopsy findings from 1976-1979 and 1995-1997. Am J Kidney Dis 1997; 30: 621-31
3. Ponticelli C. Membranous nephropathy. J Nephrol 2007; 20 (3): 268-87
4. Mathieson P. Renal disease II: membranous nephropathy. J R Coll Physicians Lond 1997; 31 (2): 133-7
5. Schieppati A, Mosconi L, Perna A. Prognosis of untreated patients with idiopathic membranous nephropathy. N Eng J Med 1993; 329: 85-9
6. Passerini P, Pasquali S, Cesana B, et al. Long-term outcome of patients with membranous nephropathy after complete remission of proteinuria. Nephrol Dial Transplant 1989; 4: 525-9
7. Troyanov S, Wall CA, Miller JA, et al. Toronto glomerulonephritis registry book: idiopathic membranous nephropathy - definition and relevance of a partial remission. Kidney Int 2004; 66: 1199-205
8. Fervenza FC, Sethi S, Specks U. Idiopathic membranous nephropathy: diagnosis and treatment. Clin J Am Soc Nephrol 2008; 3 (3): 905-19
9. Du Buf-Vereijken PW, Branten AJ, Wetzels JF. Idiopathic membranous nephropathy: outline and rationale of a treatment strategy. Am J Kidney Dis 2005; 46: 1012: 29
10. Mathieson P. Treating progressive and indolent MGN [letter]. Q J Med 1998; 91 (2): 167
11. Lai KN. Membranous nephropathy: when and how to treat. Kidney Int 2007; 71 (9): 841-3
12. Imai H. Medical decision-making in membranous nephro-pathy: how to use limited clinical research evidence in patient management. Clin Exp Nephrol 2005; 9 (3): 206-11
13. Passerini P, Lupo A, Pozzi C, et al. Therapeutic strategies for membranous nephropathy: guideline from the Italian Society of Nephrology. G Ital Nefrol 2007; 24 Suppl. 37: 13-29
14. Cameron JS. Membranous nephropathy: still a treatment dilemma. N Engl J Med 1992 Aug 27; 327 (9): 638-9 [see comment: N Engl J Med 1992; 327 (9): 599-603]
15. Perna A, Schieppati A, Zamora J, et al. Immunosup-pressive treatment for idiopathic membranous nephro-pathy: a systematic review. Am J Kidney Dis 2004; 44: 385-401
16. Shirai S, Kimura K. Lifestyle modification and diet therapy for nephrotic syndrome. Nippon Rinsho 2004; 62 (10): 1885-91
17. Giordano M, De Feo P, Lucidi P. Effects of dietary protein restriction on fibrinogen and albumin metabolism in nephrotic patients. Kidney Int 2001; 60: 235-42
18. Maroni BJ, Staffeld C, Young VR, et al. Mechanisms permitting nephrotic patients to achieve nitrogen equilibrium with a protein-restricted diet. J Clin Invest 1997; 99: 2479-87
19. Remuzzi A, Perticucci E, Battaglia C, et al. Low-protein diet and glomerular size-selective function in membranous glomerulopathy. Am J Kidney Dis 1991; 17: 317-22
20. D'Amico G, Remuzzi G, Maschio G. Effect of dietary proteins and lipids on patients with membranous nephro-pathy and nephrotic sindrome. Clin Nephrol 1991; 35: 237-42
21. Appel GB. Improved outcomes in nephrotic syndrome. Cleve Clin J Med 2006; 73 (2): 161-7
22. Glassock RJ. Prophylactic anticoagulation in nephrotic syndrome: a clinical conundrum. J Am Soc Nephrol 2007; 18 (8): 2221-5
23. Ruggenenti P, Mosconi L, Vendramin G, et al. ACE inhibition improves glomerular size selectivity in patients with idiopathic membranous nephropathy and persistent nephrotic syndrome. Am J Kidney Dis 2000; 35 (3): 381-91
24. Ruggenenti P, Cravedi P, Remuzzi G. Latest treatment strategies for membranous nephropathy. Expert Opin Pharmacother 2007; 8 (18): 3159-71
25. Praga M, Borstein B, Andres A, et al. Nephrotic proteinuria without hypoalbuminemia: clinical characteristics and response to angiotensin-converting enzyme inhibition. Am J Kidney Dis 1991; 17 (3): 330-8
26. Stegeman CA, de Zeeuw D, de Jong PE. Treatment of idiopathic membranous nephropathy: the dilemma of who, when, and how. Nephrol Dial Transplant 1995; 10 (11): 1982-4
27. Ponticelli C, Zucchelli P, Passerini P, et al. A 10-year follow-up of a randomized study with methylprednisolone and chlorambucil in membranous nephropathy. Kidney Int 1995; 48 (5): 1600-4
28. Ponticelli C, Passerini P, Altieri P, et al. Remission and relapses in idiopathic membranous nephropathy. Nephrol Dial Transplant 1992; 7 Suppl. 1: 85-90
29. Hirschberg R, Wang S. Proteinuria and growth factors in the development of tubulointerstitial injury and scarring in kidney disease. Curr Opin Nephrol Hypertens 2005; 14 (1): 43-52
30. Donadio Jr JV, Holley KE, Anderson CF, et al. Controlled trial of cyclophosphamide in idiopathic membranous nephropathy. Kidney Int 1974; 6 (6): 431-9
31. Silverberg DS, for the Western Canadian Glomerulonephritis Study Group. Controlled trial of azathioprine in the nephritic syndrome secondary to membranous glomerulonephritis. Can Med Assoc J 1976; 115: 1209-13
32. Coggins CH, for the Collaborative Study of the Adult Idiopathic Nephrotic Syndrome. A controlled study of short-term prednisone treatment I adults with membranous nephropathy. Collaborative Study of the Adult Idiopathic Nephrotic Syndrome. N Engl J Med 1979; 301: 1301-6
33. Cattran DC, Delmore T, Roscoe J, et al. A randomized controlled trial of prednisone in patients with idiopathic membranous nephropathy. N Engl J Med 1989; 320 (4): 210-5
34. Cameron JS, Healy MJ, Adu D. The Medical Research Council trial of short-term high-dose alternate day pred-nisolone in idiopathic membranous nephropathy with nephrotic syndrome in adults. The MRC Glomerulone-phritis Working Party. Q J Med 1990 Feb; 74 (274): 133-56
35. Ponticelli C, Zucchelli P, Passerini P, et al. Methylprednis-olone plus chlorambucil as compared with methylpredni-solone alone for the treatment of idiopathic membranous nephropathy. The Italian Idiopathic Membranous Nephropathy Treatment Study Group. N Engl J Med 1992 27; 327 (9): 599-603
36. Murphy BF, McDonald I, Fairley KF, et al. Randomized controlled trial of cyclophosphamide, warfarin and di-pyridamole in idiopathic membranous glomerulone-phritis. Clin Nephrol 1992; 37 (5): 229-34
37. Falk RJ, Hogan SL, Muller KE, et al., and the Glomerular Disease Collaborative Network. Treatment of progressive membranous glomerulopathy: a randomized trial comparing cyclophosphamide and corticosteroids with corti-costeroids alone. Ann Intern Med 1992 15; 116 (6): 438-45
38. Reichert LJ, Huysmans FT, Assmann K, et al. Preserving renal function in patients with membranous nephropathy: daily oral chlorambucil compared with intermittent monthly pulses of cyclophosphamide. Ann Intern Med 1994; 121 (5): 328-33
39. Cattran DC, Greenwood C, Ritchie S, et al. A controlled trial of cyclosporine in patients with progressive membranous nephropathy. Canadian Glomerulonephritis Study Group. Kidney Int 1995; 47 (4): 1130-5
40. Pisoni R, Grinyo JM, Salvatori M. Cyclosporin versus conservative therapy in patients with idiopathic membranous nephropathy (IMN) and deteriorating renal function: results of the CYCLOMEN trial [abstract]. J Am Soc Nephrol 2000; 11: A95
41. Ponticelli C, Altieri P, Scolari F, et al. A randomized study comparing methylprednisolone plus chlorambucil versus methylprednisolone plus cyclophosphamide in idiopathic membranous nephropathy. J Am Soc Nephrol 1998; 9 (3): 444-50
42. Imperiale TF, Goldfarb S, Berns JS. Are cytotoxic agents beneficialinidiopathic membranous nephropathy?A meta-analysis of the controlled trials. J Am Soc Nephrol 1995; 5 (8): 1553-8
43. Hogan SL, Muller KE, Jennette JC, et al. A review of therapeutic studies of idiopathic membranous glomerulo-pathy. Am J Kidney Dis 1995; 25 (6): 862-75
44. Ponticelli C, Villa M. Does cyclosporin have a role in the treatment of membranous nephropathy? Nephrol Dial Transplant 1999; 14 (1): 23-5
45. Cattran DC, Appel GB, Hebert LA, et al., North America Nephrotic Syndrome Study Group. Cyclosporine in patients with steroid-resistant membranous nephropathy: a randomized trial. Kidney Int 2001; 59 (4): 1484-90
46. Cattran DC, Alexopoulos E, Heering P, et al. Cyclosporin in idiopathic glomerular disease associated with the ne-phrotic syndrome: workshop recommendations. Kidney Int 2007; 72 (12): 1429-47
47. Goumenos DS, Kalliakamani P, Tsakas S, et al. The remission of nephrotic syndrome with cyclosporin treatment does not attenuate the progression of idiopathic membranous nephropathy. Clin Nephrol 2004; 61: 17-24
48. Ambalavanan S, Fauvel JP, Sibley RK, et al. Mechanism of the antiproteinuric effect of cyclosporine in membranous nephropathy. Am J Am Soc Nephrol 1996; 7 (2): 290-8
49. Goumenos DS. What have we learned from the use of ciclosporin A in the treatment of nephrotic patients with idiopathic membranous nephropathy? Expert Opin Pharmacother 2008; 9 (10): 1695-704
50. Meyrier A, Noël LH, Auriche P, et al. Long-term renal tolerance of cyclosporin A treatment in adult idiopathic nephrotic syndrome. Collaborative Group of the Société de Néphrologie. Kidney Int 1994; 45 (5): 1446-56
51. Faul C, Donnelly M, Merscher-Gomez S, et al. The actin cytoskeleton of kidney podocytes is a direct target of the antiproteinuric effect of cyclosporine A. Nat Med 2008; 14 (9): 931-8
52. Mathieson PW. Proteinuria and immunity: an overstated relationship? N Engl Med 2008; 359 (23): 2492-4
53. Mathieson PW. Is low-dose ciclosporin an effective treatment for membranous nephropathy with nephrotic syndrome? Nat Clin Pract Nephrol 2007; 3 (4): 190-1
54. Berg AL, Arnadottir M. ACTH-induced improvement in the nephrotic syndrome in patients with a variety of diagnosis. Nephrol Dial Transplant 2004; 19: 1305-97
55. Picardi L, Villa G, Galli F, et al. ACTH therapy in nephrotic syndrome induced by idiopathic membranous nephropathy. Clin Nephrol 2004; 62 (5): 403-4
56. Ponticelli C, Passerini P, Salvadori M, et al. A randomized pilot trial comparing methylprednisolone plus a cytotoxic agent versus synthetic adrenocorticotropic hormone in idiopathic membranous nephropathy. Am J Kidney Dis 2006; 47 (2):233-40
57. Sepe V, Libetta C, Giuliano MG, et al. Mycophenolate mofetil in primary glomerulopathies. Kidney Int 2008; 73 (2): 154-62
58. Appel GB, Radhakrishnan J, Ginzler EM. Use of myco-phenolate mofetil in autoimmune and renal diseases. Transplantation 2005; 80: S265-71
59. Senthil Nayagam L, Ganguli A, Rathi M, et al. Mycophe-nolate mofetil or standard therapy for membranous ne-phropathy and focal segmental glomerulosclerosis: a pilot study. Nephrol Dial Transplant 2008; 23 (6): 1926-30
60. Chan TM, Lin AW, Tang SC, et al. Prospective controlled study on mycophenolate mofetil and prednisolone in the treatment of membranous nephropathy with nephrotic syndrome. Nephrology (Carlton) 2007; 12 (6): 576-81
61. Dussol B, Morange S, Burtey S, et al. Mycophenolate mo-fetil monotherapy in membranous nephropathy: a 1-year randomized controlled trial. Am J Kidney Dis 2008; 52 (4): 699-705
62. Cattran DC. Mycophenolate mofetil and cyclosporine therapy in membranous nephropathy. Semin Nephrol 2003; 23: 272-7
63. Arikan H, Koc M, Cakalagaoglu F, et al. Tacrolimus rescue therapy in resistant or relapsing cases of primary glomerulonephritis. J Nephrol 2008; 21 (5): 713-21
64. Wetzels JF. Tacrolimus in membranous nephropathy [letter]. Kidney Int 2008; 73 (2): 238
65. Praga M, Barrio V, Juárez GF, et al., Grupo Español de Estudio de la Nefropatía Membranosa. Tacrolimus monotherapy in membranous nephropathy: a randomized controlled trial. Kidney Int 2007; 71 (9): 924-30
66. Li X, Lv R, He Q, et al. Early initiation of tacrolimus or cyclophosphamide therapy for idiopathic membranous nephropathy with severe proteinuria. J Nephrol 2008; 21 (4): 584-91
67. Ballarin J, Poveda R, Ara J, et al. Treatment of idiopathic membranous nephropathy with the combination of steroids, tacrolimus and mycophenolate mofetil: results of a pilot study. Nephrol Dial Transplant 2007; 22 (11): 3196-201
68. Levy Y, Sherer Y, George J, et al. Use of intravenous im-munoglobulin in idiopathic membranous nephropathy [letter]. Intern Med 1999 Nov; 38 (11): 917
69. Palla R, Cirami C, Panichi V, et al. Intravenous immunoglobulin therapy of membranous nephropathy: efficacy and safety. Clin Nephrol 1991; 35 (3): 98-104
70. Yokoyama H, Goshima S, Wada T, et al., Kanazawa Study Group for Renal Diseases and Hypertension. The short-and long-term outcomes of membranous nephropathy treated with intravenous immune globulin therapy. Nephrol Dial Transplant 1999; 14 (10): 2379-86
71. Orbach H, Tishler M, Shoenfeld Y. Intravenous im-munoglobulin and the kidney-a two-edged sword. Semin Arthritis Rheum 2004; 34 (3): 593-601
72. Floccari F, Cosentini V, Giacobbe M, et al. A case-by-case protocol of membranous nephropathy treatment with endovenous infusion of high doses of human immuno-globulins. Nephron Clin Pract 2008; 108 (2): 113-20
73. Taylor RP, Lindorfer MA. Immunotherapeutic mechanisms of anti-CD20 monoclonal antibodies. Curr Opin Immunol 2008; 20 (4): 444-9
74. Fervenza FC, Cosio FG, Erickson SB, et al. Rituximab treatment of idiopathic membranous nephropathy. Kidney Int 2008; 73 (1): 117-25
75. Ahmed MS, Wong CF. Rituximab and nephrotic syndrome: a new therapeutic hope? Nephrol Dial Transplant 2008; 23 (1): 11-7
76. Ring T. Rituximab in membranous nephropathy. Kidney Int 2008; 74 (3): 391-2
77. Fervenza FC, Herzenberg AM, Erickson SB, et al. Variations in response to rituximab in the treatment of idiopathic membranous nephropathy (IMN): preliminary results ay 1 year [abstract]. J Am Soc Nephrol 2006; 17: 570
78. Ruggenenti P, Chiurchiu C, Abbate M, et al. Rituximab for idiopathic membranous nephropathy: who can benefit? Clin J Am Soc Nephrol 2006; 1 (4): 738-48
79. Ruggenenti P, Cravedi P, Sghirlanzoni MC, et al. Effects of rituximab on morphofunctional abnormalities of membranous glomerulopathy. Clin J Am Soc Nephrol 2008; 3 (6): 1652-9
80. Ruggenenti P, Cravedi P, Remuzzi G. Rituximab for membranous nephropathy and immune disease: less might be enough [abstract]. Nat Clin Pract Nephrol. Epub 2008 Dec 2
81. Passerini P, Leoni A. Treatment of membranous nephropathy with chronic renal insufficiency. G Ital Nefrol 2008; 25 Suppl. 44: 76-82
82. Brunkhorst R, Wrenger E, Koch KM. Low-dose prednisolone/chlorambucil therapy in patients with severe membranous glomerulonephritis. Clin Investig 1994 Mar; 72 (4): 277-82
83. Savoldi S, Mesiano P, Rocchietti M. Problems with immunosuppressive agents in nephropathies with chronic renal failure. G Ital Nefrol 2008; 25 Suppl. 44: 38-47
84. Makino M, Honda H, Miyoshi F, et al. A fulminant case of renal vein thrombosis in a patient with autoimmune disorder and membranous nephropathy. Intern Med 2008; 47 (10): 969-73
85. Mathieson PW, Peat DS, Short A, et al. Coexistent membranous nephropathy and ANCA-positive crescentic glo-merulonephritis inassociation with penicillamine. Nephrol Dial Transplant 1996; 11 (5): 863-6
86. Nayak SG, Satish R. Crescentic transformation in primary membranous glomerulopathy: association with anti-GBM antibody. Saudi J Kidney Dis Transpl 2007 Nov; 18 (4): 599-602
87. Unver S, Haholu A, Atasoyu EM, et al. A rare complication of idiopathic membranous nephropathy: crescentic transformation. Ren Fail 2008; 30 (5): 573-5
88. Tse WY, Howie AJ, Adu D, et al. Association of vasculitic glomerulonephritis with membranous nephropathy: a report of 10 cases. Nephrol Dial Transplant 1997; 12 (5): 1017-27
89. Markowitz GS, Falkowitz DC, Isom R, et al. Membranous glomerulopathy and acute interstitial nephritis following treatment with celecoxib. Clin Nephrol 2003; 59(2): 137-42
90. Mathieson PW, Turner AN, Maidment CG, et al. Pre-dnisone and chlorambucil treatment in idiopathic membranous nephropathy with deteriorating renal function. Lancet 1988; 2: 869-72
91. Bruns FJ, Adler S, Fraley DS, et al. Sustained remission of membranous glomerulonephritis after cyclophosphamide and prednisone. Ann Int Med 1991; 114: 725-30
92. Warwick GL, Geddes CG, Boulton-Jones JM. Prednisone and chlorambucil therapy for idiopathic membranous nephropathy with progressive renal failure. Q J Med 1994; 87: 223-9
93. Jindal K, West M, Bear R, et al. Long-term benefits of therapy with cyclophosphamide and prednisone in patients with membranous glomerulonephritis and impaired renal function. Am J Kidney Dis 1992; 19: 61-7
94. Branten AJ, du Buf-Vereijken PW, Vervloet M, et al. My-cophenolate mofetil in idiopathic membranous nephro-pathy: a clinical trial with comparison to a historic control group treated with cyclophosphamide. Am J Kidney Dis 2007; 50 (2): 248-56
95. Passerini P, Como G, Vigano E. Idiopathic membranous nephropathy in the elderly. Nephrol Dial Transplant 1993; 8: 1321-5
96. Deegens JK, Wetzels JF. Membranous nephropathy in the older adult: epidemiology, diagnosis and management. Drugs Aging 2007; 24 (9): 717-32
97. Abrass CK. Treatment of membranous nephropathy in the elderly. Semin Nephrol 2003; 23 (4): 373-8
98. Bacchetta J, Juillard L, Cochat P, et al. Paraneoplastic glomerular diseases and malignancies. Crit Rev Oncol Hematol 2009 Apr; 70 (1): 39-58
99. Branten AJ, du-Buf Vereijken PW, Klasen IS, et al. Urinary excretion of beta-2 microglobulin and IgG predict prognosis in idiopathic membranous nephropathy: a validation study. J Am Soc Nephrol 2005; 16: 169-74
100. Piccoli A, Pillon L, Passerini P, et al. Therapy for idiopathic membranous nephropathy: tailoring the choice by decision analysis. Kidney Int 1994; 45 (4): 1193-202
101. Pahari DK, Das S, Dutta BN, et al. Prognosis and management of membranous nephropathy. J Assoc Physicians India 1993; 41 (6): 350-1
102. Ahmed S, Rahman M, Alam MR. Methylprednisolone plus chloraumbucil as compared with prednisolone alone for the treatment of idiopathic membranous nephropathy. Bangladesh Ren J 1994; 13: 51-4
103. Jha V, Kohli HS, Sud K, et al. Randomized controlled trial of steroids and cyclophosphamide in adults with idio-pathic membranous nephropathy [abstract]. J Am Soc Nephrol 2001; 12: A213